S&P 500   3,329.03 (-0.67%)
DOW   27,365.65 (-0.79%)
QQQ   276.76 (-0.16%)
AAPL   114.07 (-0.77%)
MSFT   207.66 (-0.85%)
FB   259.44 (+1.02%)
GOOGL   1,459.48 (+0.06%)
AMZN   3,164.64 (-0.30%)
TSLA   425.17 (+0.94%)
NVDA   530.78 (+1.80%)
BABA   277.25 (+0.45%)
CGC   14.59 (+2.67%)
MU   50.94 (+2.45%)
GE   6.08 (-1.94%)
AMD   82.00 (+3.17%)
T   28.20 (-0.63%)
F   6.59 (-1.49%)
ACB   4.85 (+1.46%)
GILD   62.10 (-1.19%)
NFLX   493.51 (+0.58%)
DIS   124.13 (-1.48%)
BA   163.57 (-1.51%)
BAC   23.69 (-1.66%)
S&P 500   3,329.03 (-0.67%)
DOW   27,365.65 (-0.79%)
QQQ   276.76 (-0.16%)
AAPL   114.07 (-0.77%)
MSFT   207.66 (-0.85%)
FB   259.44 (+1.02%)
GOOGL   1,459.48 (+0.06%)
AMZN   3,164.64 (-0.30%)
TSLA   425.17 (+0.94%)
NVDA   530.78 (+1.80%)
BABA   277.25 (+0.45%)
CGC   14.59 (+2.67%)
MU   50.94 (+2.45%)
GE   6.08 (-1.94%)
AMD   82.00 (+3.17%)
T   28.20 (-0.63%)
F   6.59 (-1.49%)
ACB   4.85 (+1.46%)
GILD   62.10 (-1.19%)
NFLX   493.51 (+0.58%)
DIS   124.13 (-1.48%)
BA   163.57 (-1.51%)
BAC   23.69 (-1.66%)
S&P 500   3,329.03 (-0.67%)
DOW   27,365.65 (-0.79%)
QQQ   276.76 (-0.16%)
AAPL   114.07 (-0.77%)
MSFT   207.66 (-0.85%)
FB   259.44 (+1.02%)
GOOGL   1,459.48 (+0.06%)
AMZN   3,164.64 (-0.30%)
TSLA   425.17 (+0.94%)
NVDA   530.78 (+1.80%)
BABA   277.25 (+0.45%)
CGC   14.59 (+2.67%)
MU   50.94 (+2.45%)
GE   6.08 (-1.94%)
AMD   82.00 (+3.17%)
T   28.20 (-0.63%)
F   6.59 (-1.49%)
ACB   4.85 (+1.46%)
GILD   62.10 (-1.19%)
NFLX   493.51 (+0.58%)
DIS   124.13 (-1.48%)
BA   163.57 (-1.51%)
BAC   23.69 (-1.66%)
S&P 500   3,329.03 (-0.67%)
DOW   27,365.65 (-0.79%)
QQQ   276.76 (-0.16%)
AAPL   114.07 (-0.77%)
MSFT   207.66 (-0.85%)
FB   259.44 (+1.02%)
GOOGL   1,459.48 (+0.06%)
AMZN   3,164.64 (-0.30%)
TSLA   425.17 (+0.94%)
NVDA   530.78 (+1.80%)
BABA   277.25 (+0.45%)
CGC   14.59 (+2.67%)
MU   50.94 (+2.45%)
GE   6.08 (-1.94%)
AMD   82.00 (+3.17%)
T   28.20 (-0.63%)
F   6.59 (-1.49%)
ACB   4.85 (+1.46%)
GILD   62.10 (-1.19%)
NFLX   493.51 (+0.58%)
DIS   124.13 (-1.48%)
BA   163.57 (-1.51%)
BAC   23.69 (-1.66%)
Log in
NASDAQ:FONR

Fonar Stock Forecast, Price & News

$22.05
-0.20 (-0.90 %)
(As of 09/29/2020 10:37 AM ET)
Add
Compare
Today's Range
$22.05
Now: $22.05
$22.05
50-Day Range
$21.81
MA: $25.12
$26.49
52-Week Range
$11.00
Now: $22.05
$26.49
Volume1 shs
Average Volume37,735 shs
Market Capitalization$142.18 million
P/E Ratio12.60
Dividend YieldN/A
Beta1.13
FONAR Corporation, together with its subsidiaries, operates as a magnetic resonance imaging (MRI) company primarily in the Unites States. It is involved in the research, development, production, and marketing of medical scanning equipment, which uses principles of MRI for the detection and diagnosis of human diseases, abnormalities, other medical conditions, and injuries. The company operates in two segments, Manufacturing and Servicing of Medical Equipment, and Management of Diagnostic Imaging Centers. It provides Upright MRI scanner that allows patients to be scanned in weight-bearing conditions, such as standing, sitting, bending, or lying down. The company markets its scanners to private diagnostic imaging centers and hospitals. It also provides non-medical management services, including development, administration, office space leasing, facilities, equipment, supplies, staffing, credentialing, accounting, billing and collection, assistance with compliance matters, and practice growth and marketing strategies development and implementation services, as well as engages in the training and supervision of non-medical personnel for diagnostic imaging facilities. The company also exports its products to the United Arab Emirates, Switzerland, Canada, England, Germany, and Puerto Rico. It owns and operates 4 diagnostic imaging facilities in Florida; and manages 26 MRI scanning facilities, including 19 facilities located in New York and 7 situated in Florida. The company was founded in 1978 and is based in Melville, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.01 out of 5 stars


Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FONR
CUSIPN/A
Phone631-694-2929

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$87.19 million
Cash Flow$2.57 per share
Book Value$18.58 per share

Profitability

Net Income$15.32 million

Miscellaneous

EmployeesN/A
Market Cap$142.18 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$22.05
-0.20 (-0.90 %)
(As of 09/29/2020 10:37 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FONR News and Ratings via Email

Sign-up to receive the latest news and ratings for FONR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Fonar (NASDAQ:FONR) Frequently Asked Questions

How has Fonar's stock price been impacted by COVID-19 (Coronavirus)?

Fonar's stock was trading at $15.20 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, FONR shares have increased by 45.1% and is now trading at $22.05.
View which stocks have been most impacted by COVID-19
.

When is Fonar's next earnings date?

Fonar is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Fonar
.

How were Fonar's earnings last quarter?

Fonar Co. (NASDAQ:FONR) posted its earnings results on Monday, May, 11th. The medical equipment provider reported $0.18 EPS for the quarter. The medical equipment provider had revenue of $21.69 million for the quarter. Fonar had a net margin of 13.16% and a return on equity of 9.35%.
View Fonar's earnings history
.

Who are some of Fonar's key competitors?

What other stocks do shareholders of Fonar own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fonar investors own include Gilead Sciences (GILD), Amarin (AMRN), Crispr Therapeutics (CRSP), Exelixis (EXEL), Pfizer (PFE), Bausch Health Companies (BHC), Incyte (INCY), Jazz Pharmaceuticals (JAZZ), Lannett (LCI) and Madrigal Pharmaceuticals (MDGL).

Who are Fonar's key executives?

Fonar's management team includes the following people:
  • Dr. Raymond V. Damadian, Chairman, Principal Financial Officer & Treasurer (Age 83)
  • Mr. Timothy R. Damadian, CEO & Pres (Age 55)
  • Mr. Luciano B. Bonanni, COO & Exec. VP (Age 64)
  • Ms. Claudette J. V. Chan, Sec. & Director (Age 81)
  • Mr. Daniel Culver, Director of Communications

What is Fonar's stock symbol?

Fonar trades on the NASDAQ under the ticker symbol "FONR."

How do I buy shares of Fonar?

Shares of FONR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Fonar's stock price today?

One share of FONR stock can currently be purchased for approximately $22.05.

How big of a company is Fonar?

Fonar has a market capitalization of $142.18 million and generates $87.19 million in revenue each year.

What is Fonar's official website?

The official website for Fonar is www.fonar.com.

How can I contact Fonar?

Fonar's mailing address is 110 Marcus Drive, Melville NY, 11747. The medical equipment provider can be reached via phone at 631-694-2929 or via email at [email protected]

This page was last updated on 9/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.